Terry Pearson

CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada.

CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada.

CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada.

Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation.